Skip to main content
Clinical Trials/NCT03776682
NCT03776682
Completed
Not Applicable

Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study

Mayo Clinic1 site in 1 country35 target enrollmentJune 22, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myocardial Inflammation
Sponsor
Mayo Clinic
Enrollment
35
Locations
1
Primary Endpoint
Subclinical myocardial inflammatory burden as detected by PET imaging
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Rheumatoid arthritis (RA) patients have a higher prevalence of subclinical atherosclerosis than the general population. In addition, RA patients experience higher rates of heart failure with preserved ejection fraction (HFpEF). There is evidence that myocardial mechanics and left ventricular diastolic function are more abnormal in the RA population and these changes occur earlier than in the general population. Recently a study suggested that RA patient have abnormal myocardial inflammation during a disease flare and that this is improved with anti-inflammatory treatment. This study is aimed at describing the prevalence of myocardial inflammation in patients during active RA disease flares and comparing that with RA patients who are in remission. Investigators hope to show that abnormalities in myocardial inflammation on PET imaging correlate with abnormalities in myocardial strain on echocardiography. Coronary CT will be performed to establish the presence of subclinical atherosclerosis and whether its presence affects changes in either myocardial inflammation or myocardial strain. The hypothesis is that patients with evidence of myocardial inflammation during the course of their RA disease are more likely to develop HFpEF during their lifetime. Although the present study will not be of a duration to assess outcome, it will provide descriptive data which may help guide future prospective study of patients with RA which may help guide appropriate cardiovascular testing in this high risk population.

Registry
clinicaltrials.gov
Start Date
June 22, 2018
End Date
May 26, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rekha Mankad

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Subclinical myocardial inflammatory burden as detected by PET imaging

Time Frame: 14 days

To determine if myocardial F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with rheumatoid arthritis reveals evidence of subclinical myocardial inflammation which correlate with level of systemic inflammatory burden.

Relationship of presence of myocardial inflammation to atherosclerotic burden

Time Frame: 7 days

To determine if mild to moderate atherosclerotic plaque burden on coronary computed tomographic angiography (CCTA) correlates with the degree of myocardial inflammation as assessed by FDG PET.

Study Sites (1)

Loading locations...

Similar Trials